Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy

Inclusion criteria: * Histologic or cytologic diagnosis of advanced non-small-cell lung cancer (NSCLC) * Based on International Association for the Study of Lung Cancer (IASLC) 2009 new Tumor-Node-Metastasis (TNM) stage criteria of lung cancer, local advanced stage IIIB (not applicable for radical radiation therapy) disease or metastatic stage IV disease or recurrent disease * At least one evaluable tumor lesion based on RECIST criteria (\>= 20 mm with conventional techniques or \>= 10 mm with spiral Computed Tomography scan) * Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1 * Adequate bone marrow reserve * absolute neutrophil count \>= 2.0×10\^9/L * platelets \>= 100×10\^9/L * hemoglobin \>= 9.0 g/dL * Adequate hepatic function * total bilirubin \<= Upper Normal Limit (UNL) * Aspartate Amino Transferase (AST), Alanine Amino Transferase (ALT) \<= 2.5 UNL * alkaline phosphatase (ALP) \<= 5 UNL * Adequate renal function (serum creatinine \<= UNL or creatinine clearance \>= 60 mL/min) * No prior chemotherapy was allowed or only (neo) adjuvant chemotherapy ended more than 6 months before treatment (patients should not have been heavily pre-treated, the maximum cumulative dose of cisplatin allowed is 350 mg/m²) * Prior surgery was permitted only if the operation performed more than 4 weeks ago and the patient was completely recovery * Childbearing potential either terminated or attenuated by the use of an approved contraceptive method * Inform consent signed Exclusion criteria: * Other tumour type than advanced / metastatic NSCLC in recent 5 years (except cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous cell carcinoma of the skin). * Presence of symptomatic central nervous system metastases * Inadequate liver function * total bilirubin \> 1 UNL * ALT and/or AST\>1.5 UNL associated with alkaline phosphatase \> 2.5 UNL * inadequate renal function (creatinine \> 1.0 times UNL and in case of limit value, creatinine clearance \< 60 mL/min) * Prior radiation therapy, or surgery operation within 4 weeks * Prior use of taxoids * Active infection, or serious concomitant systemic disorder incompatible with the study * Childbearing potential but unwilling to use of an approved contraceptive method * Receive treatment from other clinical trials during this study treatment * History of hypersensitivity to any of study medication * Other serious concomitant abnormal or illness The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.